A Phase 2 interventional study of AGA2115 and Placebo in Osteogenesis Imperfecta (OI), sponsored by Angitia Incorporated Limited. Recruiting at 26 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Angitia Incorporated Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Osteogenesis Imperfecta with a site in United States — 4 open to participants now, 11 under way, 4 of them phase 3. Osteogenesis Imperfecta · United States.
Among the 38 studies in Osteogenesis Imperfecta with a site in United States, this one is the 9th largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2025, is one of 7 in phase 2, reaches primary completion later than 7 of the 10 other live ones, and was the 37th registered.
84 studies on the registry are indexed under Osteogenesis Imperfecta; 20 are open to participants now.
Browse Osteogenesis Imperfecta studies →4 of the 38 studies in Osteogenesis Imperfecta with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States, Belgium, China and 3 more countries
Ages 5–19
Hospital for Special Surgery, New York · Sites in United States
Ages 6–100 · Healthy volunteers
Baylor College of Medicine · Sites in United States, Canada
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Osteogenesis Imperfecta studies recruiting now, 4 (29%) set no upper age limit and 8 (57%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 9 · Phase 4 2
First in 1991; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 28 across 60 interventional studies indexed under Osteogenesis Imperfecta.
Median enrollment 63 across the 28 interventional studies, 82 across the 10 observational. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 38 have an industry lead sponsor. The 10 most frequent:
Angitia Incorporated Limited is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Angitia Incorporated Limited has 2 studies filed under Osteogenesis Imperfecta — fewer than ten, so there is no comparison to draw.
5 of the studies in Osteogenesis Imperfecta with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05972551Phase 3AmgenStudy to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta | 2027-05-04 |
| NCT04152551Hospital for Special Surgery, New YorkEffects of Bisphosphonates on OI-Related Hearing Loss | 2027-01 |
| NCT04815564Baylor College of MedicineClear Aligners for the Treatment of Dental Malocclusion in OI | 2027-08-01 |
| NCT05317637Baylor College of MedicineCardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708 | 2027-08-31 |
| NCT07062588Angitia Incorporated LimitedOsteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN) | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 38 studies in Osteogenesis Imperfecta with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.
This Phase 2 dose-ranging study will evaluate the safety and efficacy of AGA2115 at a range of doses in adults with Type I, III, or IV osteogenesis imperfecta. The study will last 27 months with a 24-month treatment period and a 3-month follow-up period. During the first 12 months of the study, participants will be randomized 1:1:1:1 to receive either placebo or one of three dose levels of AGA2115 doses; treatment assignment will be double-blind. Months 12 to 24 will be open-label, and all participants will receive AGA2115. Participants will attend visits where safety and efficacy parameters will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants that complete the double-blind period receiving AGA2115 Dose 1 from study start to Month 12 will continue to a 12-month open-label period. Participants will then receive AGA2115 Dose 2 for Months 12 to 24.
Drug: AGA2115
Participants that complete the double-blind period receiving AGA2115 Dose 2 from study start to Month 12 will continue to a 12-month open-label period. Participants will be kept on the same AGA2115 dose for Months 12 to 24.
Drug: AGA2115
Participants that complete the double-blind period receiving AGA2115 Dose 3 from study start to Month 12 will continue to a 12-month open-label period. Participants will receive the same AGA2115 dose for Months 12 to 24.
Drug: AGA2115
Participants that complete the double-blind period receiving placebo from study start to Month 12 will continue to a 12-month open-label period. Participants will receive AGA2115 Dose 3 for Months 12 to 24.
Other: Placebo
Subcutaneous injection
Subcutaneous injection
Percent change from Baseline at Month 12 in lumbar spine BMD
Time frame: 12 months
Percent change from Baseline at Month 3 and 6 in lumbar spine, total hip, femoral neck, one-third distal radius, and total body (minus head) BMD
Time frame: 3 and 6 months
Percent change from Baseline at Month 12 in total hip, femoral neck, one-third distal radius, and total body (minus head) BMD
Time frame: 12 months
Percent change from Baseline at Week 1 and Month 1, 3, 6, 9, and 12 in P1NP and CTX-1
Time frame: Week 1, Month 1, 3, 6, 9, and 12
Percentage of participants with fractures during the double-blind treatment period
Time frame: up to 12 months
Annualized fracture rate for incident fractures occurring during the double-blind treatment period (total, long-bone, vertebral, peripheral)
Time frame: up to 12 months
Assessment of TEAEs (collection and documentation of all adverse events occurring during the study)
Time frame: Baseline to 24 months
Evaluation of AGA2115 observed serum concentration levels for the AGA2115 treatment groups
Time frame: Baseline to 24 months
Number of participants who develop anti-AGA2115 antibodies
Time frame: Baseline to 24 months
Started Dec 2025 (actual). Primary completion is estimated for Nov 2027, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Humanized bispecific antibody neutralizing both sclerostin AND DICKKOPF-1 (AGA-2115)
Angitia Incorporated Limited